Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.21.2
Note 3 - Revenue From Contracts With Customers (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Royalty revenue:

                               

Tc99m tilmanocept - Europe

  $     $ 2,047     $     $ 26,188  
                                 

License revenue:

                               

Tc99m tilmanocept - Europe

  $ 9,116     $ 4,726     $ 44,665     $ 4,726  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Total deferred revenue, beginning of period

  $ 700,000     $ 860,000     $ 700,000     $ 700,000  

Revenue deferred related to sublicense

                      160,000  

Refund of deferred revenue related to sublicense

          (160,000

)

          (160,000

)

Revenue recognized from satisfaction of performance obligations

                       

Total deferred revenue, end of period

  $ 700,000     $ 700,000     $ 700,000     $ 700,000